Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L.
Liu D, et al.
BMC Med. 2022 Oct 25;20(1):408. doi: 10.1186/s12916-022-02605-9.
BMC Med. 2022.
PMID: 36280870
Free PMC article.
Clinical Trial.